Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Azenta, Inc. (Nasdaq: AZTA), a life sciences company focused on cold-chain sample management and multiomics services. These regulatory documents offer detailed insight into how Azenta reports its financial performance, governance practices and executive compensation.
Core filings include the annual report on Form 10-K and quarterly updates on Form 10-Q, where Azenta discusses revenue from its Sample Management Solutions and Multiomics segments, separates products and services revenue, and explains trends in gross margin, operating expenses and adjusted EBITDA. Investors can review these filings to understand the contribution of sample storage, biorepository services and genomic analysis to the overall business.
Azenta’s current report filings on Form 8-K disclose material events such as quarterly and annual financial results, including segment performance and key metrics. For example, the company has furnished press releases detailing revenue growth, margin expansion and cash and liquidity positions, which are incorporated by reference into 8-K filings under Item 2.02.
The definitive proxy statement on Schedule 14A (DEF 14A) describes the structure of the Board of Directors, committee responsibilities, environmental, social and governance topics, and the executive compensation framework. It also outlines proposals submitted to shareholders, such as the election of directors, advisory votes on executive pay, amendments to the equity incentive plan and ratification of the independent auditor.
On Stock Titan, Azenta’s filings are updated as they appear on EDGAR, and AI-powered summaries can help explain lengthy documents like the 10-K, 10-Q, 8-K and DEF 14A. Users can quickly identify segment disclosures, non-GAAP reconciliations, compensation details and other key items without reading every page of the underlying filing.
Azenta, Inc. is asking shareholders to vote at a virtual-only annual meeting on January 28, 2026, with a record date of December 3, 2025. Shareholders will elect ten directors, hold an advisory vote on executive pay, approve an increase of 2,750,000 shares reserved under the 2020 Equity Incentive Plan, and ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
The board is led by an independent chair, and nine of ten director nominees are independent, with an average tenure of 2.7 years and 40% gender, racial or ethnic diversity. Azenta highlights ESG oversight, board refreshment, and strong governance practices, including annual say-on-pay and stock ownership guidelines. The company reports fiscal 2025 revenue growth of 4% (3% organic) and 310 basis points of margin expansion, and is pursuing a sale of its B Medical business, which has been reclassified as discontinued operations.
Azenta, Inc. (AZTA) reported an equity award to its President and CEO, John Marotta. On 11/24/2025 he received a grant of 122,269 restricted stock units (RSUs) of Azenta common stock at a price of $0.00 per unit, recorded as an acquisition of non-derivative securities. Following this grant, he beneficially owns 217,268.78 shares of common stock.
The RSU award was sized by dividing a target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting, with 33-1/3% of the units scheduled to vest each year, beginning on November 24, 2026.
Azenta, Inc. (AZTA) executive Lawrence Y. Lin reported an equity award of company stock. On 11/24/2025, the EVP, CFO and Treasurer received a grant of 36,681 restricted stock units (RSUs) of Azenta common stock at a price of $0.00 per unit. Following this grant, he beneficially owns 79,655 shares of Azenta common stock in total, held directly.
The RSUs are subject to time-based vesting and are scheduled to vest in three equal annual installments of 33-1/3% each year, beginning on November 24, 2026. The number of RSUs granted was calculated by dividing a target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date.
Azenta, Inc. (AZTA) reported an equity compensation grant to one of its senior executives. On November 24, 2025, the company granted 16,303 restricted stock units (RSUs) of its common stock to its SVP and Chief Human Resources Officer, Olga Pirogova, with no cash paid upon grant and a stated price of $0.00 per unit.
The filing states that the number of RSUs was determined by dividing the target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting, with 33 1/3% vesting each year beginning on November 24, 2026. Following this grant, the reporting person beneficially owns 33,038 shares of Azenta common stock.
Azenta, Inc. (AZTA) reported an equity award to one of its senior executives. On 11/24/2025, the company’s SVP and GM, Multiomics received 13,042 restricted stock units (RSUs) of Azenta common stock at a grant price of $0.00 per unit. After this grant, the executive beneficially owns 38,755 shares of Azenta common stock in total, held directly.
The filing explains that the RSU amount was calculated by dividing the target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting and will vest in three equal installments of 33 1/3% per year, starting on November 24, 2026.
Azenta, Inc. (AZTA) reported an equity award to a senior executive. On November 24, 2025, the company’s SVP, General Counsel & Secretary acquired 34,235 shares of common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share. Following this grant, the executive beneficially owns 72,014 shares of Azenta common stock in direct ownership.
The RSUs were granted based on a target award value divided by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting and will vest in three equal installments of 33-1/3% per year, beginning on November 24, 2026.
Azenta, Inc. (AZTA) reported that a company director filed an amended Form 4 to correct earlier reporting of share purchases in May 2025. The director bought 100 shares on May 16, 2025 at $26.50, 4,152 shares on May 19, 2025 at $26.98, and 2,748 shares on May 20, 2025 at $27.37, all coded as open‑market purchases (code "P").
The amendment fixes administrative errors in the original filing that had understated the director’s beneficial ownership after each trade. The corrected beneficially owned share totals are 18,895 after the first purchase, 23,047 after the second, and 25,795 after the third, replacing previously miscalculated figures of 14,855, 19,007, and 21,755 shares.
Azenta, Inc. (AZTA) director filing correction: This Form 4/A amends a prior Form 4 for director William L. Cornog to fix an administrative error in his reported share ownership. After a grant of 4,040 restricted stock units on 02/04/2025, the original filing incorrectly showed 4,040 shares beneficially owned. The corrected figure is 18,795 shares of common stock underlying restricted stock units held directly. The amendment does not reflect a new transaction, only an updated and higher beneficial ownership amount for the same grant.
Azenta, Inc. (AZTA) director Martin Madaus filed an amended Form 4 to correct a prior administrative error in his reported shareholdings. The original Form 4, filed on February 11, 2025, had miscalculated the number of shares beneficially owned after a grant of 4,040 shares. The amendment clarifies that the correct number of shares beneficially owned following the transaction is 11,445 shares, not 4,040. The derivative position is reported as restricted stock units with a conversion price of $0, directly owned. This change does not reflect a new transaction but a correction to previously reported ownership.
Azenta, Inc. filed a current report announcing that it has released its financial results for the fiscal quarter and fiscal year ended September 30, 2025. The company disclosed that these results are contained in an earnings press release dated November 21, 2025, which is included as Exhibit 99.1 to the report and incorporated by reference. Azenta notes that this earnings information is being furnished under Item 2.02 of the Exchange Act and is not deemed filed for liability purposes under Section 18 or automatically incorporated into other securities law filings.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
